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Misfolding of amyloid-beta (Ab) has
been implicated in Alzheimer’s disease
(AD). Recent studies have shown that
early oligomeric intermediates formed
in the misfolding pathway are the main
toxic species as they kill neuronal
cells. Therefore, the development of
compounds to inhibit Ab aggrega-
tion—and thus to avoid the formation
of toxic oligomeric intermediates—is
urgently needed as they could be po-
tential drugs to treat AD (1). Although
this has been well realized by the sci-
entific community and many research
groups have been working on devel-
oping such compounds, the main limi-
tation has been the lack of biophysical
techniques that can provide atomic-
level structural insights into the mis-
folding process. Fortunately, NMR
techniques can be utilized to obtain
such high-resolution information on
amyloid peptides and proteins as
demonstrated by recent studies. In
this context, the study by Raditsis
et al. (2) demonstrates the value of so-
lution NMR techniques in understand-
ing the molecular basis for inhibition
of oligomerization Ab142 (and also a
peptide fragment Ab1228) by the
iron-transport glycoprotein transferrin
that is present in plasma and cerebro-
spinal fluid (2). Specifically, using
off-resonance relaxation and saturation
transfer difference NMR experiments,http://dx.doi.org/10.1016/j.bpj.2013.05.004
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erentially binds to Ab oligomers and
inhibits the aggregation of monomers
into large oligomers. The similarity
between the mechanisms of Ab self-
association inhibition by transferrin
and another plasma protein human
serum albumin (3) is intriguing, and in-
dicates that the Ab-oligomer-binding
model proposed in this study could be
a general strategy shared by multiple
plasma proteins.
In fact, to fully understand the Ab
toxicity, it is essential to solve the
three-dimensional structures of early
oligomers as they provide insights
into molecular interactions that drive
the misfolding and aggregation of
Ab. Although NMR is one of the
most commonly used biophysical
tools in structural biology, its poor
sensitivity severely limits structural
investigation of fast aggregating
amyloid proteins. Increasing the
amount of peptide/protein or tempera-
ture to enhance NMR sensitivity is
not desirable, for it increases the rate
of amyloid aggregation. In addition,
the presence of heterogeneous
species—monomers, oligomers, and
protofibers—significantly lower the
spectral resolution though only the
fast-tumbling small size species are
detected in solution NMR measure-
ments. Despite these limitations, a
recent NMR study determined the
high-resolution structure of Ab1-40
from solution that could be a nucleus
in the aggregation process (Fig. 1 A).
Remarkably, the NMR structure re-
veals that the hydrophobic H13–D23
region of Ab1-40 forms a 310 helix
and the unstructured hydrophobic
residues of the N- and C-termini
collapse against the central 310 helix
(4). Though previous studies have de-
tected the formation of a transient,
on-pathway a-helical intermediate, to
our knowledge this is the first experi-
mentally determined high-resolution
structure of Ab1-40 (5). This structure
is increasingly utilized in the develop-
ment of compounds to inhibit the
aggregation of Ab peptides.Because large oligomers are not de-
tected in solution NMR experiments,
NMR signals detected from monomers
are used to characterize Ab-ligand
and Ab-protein interactions (6–9).
Such studies have been used to develop
compounds that can inhibit Ab aggre-
gation as well as avoid metal-induced
aggregation by modulating the inter-
action between the metal (e.g., Cu(II)
and Zn(II)) and the peptide (6,7,9)
(Fig. 1 B). In fact, simple high-
throughput two-dimensional NMR
experiments such as NOESY, HSQC,
TROSY-HSQC, or SOFAST-HMQC
are increasingly utilized to:
1. Identify direct interactions (struc-
tures) of compounds with Ab at
a molecular level, which leads to
a better design or optimization of
molecules to efficiently suppress
the formation of toxic Ab species;
and
2. Screen a chemical library against
Ab aggregation in a high-
throughput manner. Recent studies
have demonstrated the feasibility
of real-time measurement of the
aggregation of Ab and IAPP using
19F NMR (10,11).
These studies have revealed the
formation of several different types
of small-size Ab oligomers, the non-
existence of appreciable nonfibrillar
islet amyloid polypeptide protein
intermediates, and the effect of an
amyloid inhibitor epigallocatechin
gallate (10,11). Due to both funda-
mental and translation aspects, drug
discovery for multiple targets in hu-
man diseases including the misfolding
proteins (amyloids) has been assisted
and will continue to greatly benefit by
the development and applications of
NMR spectroscopy. In this context,
the results reported by Raditsis et al.
(2) are exciting and further demon-
strate the power of simple NMR ex-
periments to characterize protein-Ab
interactions. At the same time, it
FIGURE 1 (A) A partially folded structure of Ab1-40 (PDB:2LFM) in solution determined by NMR
spectroscopy (4). (B) NMR investigations for identification of interactions of Ab with proteins, metal
ions, and/or small molecules (6–9).
288 Ramamoorthy and Limshould also be realized that the investi-
gation of the Ab-membrane interaction
and the roles of membrane components
are essential to understanding the
mechanism of Ab toxicity in AD (12).REFERENCES
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